Hui-Ju Ch’ang

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yi‐Chih Tsai · 3 shared papers, 2021–2023 · strength 0.58
   • Paper Krüppel-like Factor 10 as a Prognostic and Predictive Biomarker of Radiotherapy in Pancreatic Adenocarcinoma. DOI 10.3390/cancers15215212↗
   • Paper Krüppel-like factor 10 modulates stem cell phenotypes of pancreatic adenocarcinoma by transcriptionally regulating notc… DOI 10.1186/s12929-023-00937-z↗
   • Paper Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-lik… DOI 10.1038/s12276-021-00687-8↗
2. Yen‐Feng Chiu · 4 shared papers, 2011–2023 · strength 0.45
   • Paper Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected P… DOI 10.1016/j.ijrobp.2023.02.061↗
   • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
   • Paper The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Sy… DOI 10.4143/crt.2017.105↗
3. Li‐Tzong Chen · 4 shared papers, 2011–2023 · strength 0.45
   • Paper Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected P… DOI 10.1016/j.ijrobp.2023.02.061↗
   • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
   • Paper The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Sy… DOI 10.4143/crt.2017.105↗
4. I‐Shiow Jan · 1 shared paper, 2023 · strength 0.39
   • Paper Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy. DOI 10.1186/s13014-023-02328-y↗
5. Yan‐Shen Shan · 3 shared papers, 2011–2023 · strength 0.34
   • Paper Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected P… DOI 10.1016/j.ijrobp.2023.02.061↗
   • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
   • Paper Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiot… DOI 10.1016/j.ijrobp.2010.10.034↗
6. Chung‐Pin Li · 2 shared papers, 2022–2023 · strength 0.32
   • Paper Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected P… DOI 10.1016/j.ijrobp.2023.02.061↗
   • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
7. Long‐Sheng Lu · 1 shared paper, 2025 · strength 0.30
   • Paper Role of Neoadjuvant Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma-A Systema… DOI 10.1016/j.ijrobp.2025.02.037↗
8. Hongyan Wu · 1 shared paper, 2025 · strength 0.30
   • Paper Role of Neoadjuvant Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma-A Systema… DOI 10.1016/j.ijrobp.2025.02.037↗
9. Jen‐Shi Chen · 2 shared papers, 2011–2023 · strength 0.20
   • Paper Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected P… DOI 10.1016/j.ijrobp.2023.02.061↗
   • Paper Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiot… DOI 10.1016/j.ijrobp.2010.10.034↗
10. Tsann‐Long Hwang · 2 shared papers, 2011–2023 · strength 0.20
    • Paper Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected P… DOI 10.1016/j.ijrobp.2023.02.061↗
    • Paper Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiot… DOI 10.1016/j.ijrobp.2010.10.034↗
11. Tze‐Sing Huang · 1 shared paper, 2023 · strength 0.19
    • Paper Krüppel-like factor 10 modulates stem cell phenotypes of pancreatic adenocarcinoma by transcriptionally regulating notc… DOI 10.1186/s12929-023-00937-z↗
12. Vincent Hung-Shu Chang · 1 shared paper, 2021 · strength 0.15
    • Paper Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-lik… DOI 10.1038/s12276-021-00687-8↗
13. Nai‐Jung Chiang · 1 shared paper, 2022 · strength 0.15
    • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
14. Yung‐Yeh Su · 1 shared paper, 2022 · strength 0.15
    • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
15. Shih‐Hung Yang · 1 shared paper, 2022 · strength 0.15
    • Paper A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced panc… DOI 10.1038/s41416-021-01649-7↗
16. Jeffrey Shu-Ming Chang · 1 shared paper, 2018 · strength 0.11
    • Paper The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Sy… DOI 10.4143/crt.2017.105↗
17. Yu‐Wen Tien · 1 shared paper, 2011 · strength 0.02
    • Paper Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiot… DOI 10.1016/j.ijrobp.2010.10.034↗
18. Ann‐Lii Cheng · 1 shared paper, 2011 · strength 0.02
    • Paper Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiot… DOI 10.1016/j.ijrobp.2010.10.034↗
19. Ming‐Chu Chang · 1 shared paper, 2011 · strength 0.02
    • Paper Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiot… DOI 10.1016/j.ijrobp.2010.10.034↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.